

## FORM 7

### **MONTHLY PROGRESS REPORT**

Name of Listed Issuer: **Avisa Diagnostics Inc.** (the "Issuer").

Trading Symbol: **AVBT**

Number of Outstanding Listed Securities: **59,567,784 (43,241,310 common and 16,326,474 Class A convertible restricted voting shares)**

Date: **October 4, 2021**

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

#### **General Instructions**

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

## Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

**Avisa Diagnostics Inc. ("Avisa") is a clinical-stage medical device company developing the Avisa BreathTest™, a novel drug/device biomarker technology platform that enables the ultrarapid detection of virulent bacterial pathogens, detecting and monitoring bacterial load after the patient inhales or ingests its proprietary drug substrates.**

**September 2021 operations activity was primarily focused on the continued development of the Avisa BreathTest™.**

2. Provide a general overview and discussion of the activities of management.

**Management activity in September 2021 was mainly focused on aligning resources to prepare for the Company's Investigational Device Exemption submission to the FDA.**

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

**Avisa is working on the development of the new VAP Link, a medical device that does not interrupt the venting cycles when capturing breath from a patient on a mechanical ventilator. The VAP Link is an important piece of enabling technology that enables the fractionated breath capture necessary for the Avisa BreathTest™ to be used with ventilated patients susceptible to ventilator associated pneumonia ("VAP").**

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

**N/A**

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

**N/A**

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

**N/A**

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

**N/A**

8. Describe the acquisition of new customers or loss of customers.

**N/A**

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

**N/A**

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

**Barbara Bunger Ph.D., Vice President, Clinical Development, resigned effective September 21, 2021.**

11. Report on any labour disputes and resolutions of those disputes if applicable.

**N/A**

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

**N/A**

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

**N/A**

14. Provide details of any securities issued and options or warrants granted.

**N/A**

15. Provide details of any loans to or by Related Persons.

**David Joseph provided an unsecured loan to the Company on September 28, 2021 for US\$35,000.**

16. Provide details of any changes in directors, officers or committee members.

**N/A**

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

**Due to the COVID-19 pandemic, the need for rapid, point of care testing has been imperative. Avisia believes this trend will only increase and that its breath test technology is well positioned to capitalize on this trend as it continues well into the future.**

## Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated October 4, 2021.

Name of Director or Senior Officer

David Joseph

"David Joseph"

Signature

CEO

Official Capacity

<b>Issuer Details</b> Name of Issuer Avisa Diagnostics Inc.	For Month End September 2021	Date of Report YY/MM/D 21/10/04
Issuer Address 1199 West Hastings St., Suite 1400		
City/Province/Postal Code Vancouver BC, V6E 3T5	Issuer Fax No.	Issuer Telephone No. 610-947-0360
Contact Name David Joseph	Contact Position CEO	Contact Telephone No. 610-947-0360
Contact Email Address info@avisadx.com	Web Site Address http://www.avisadx.com	